| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie |
2020-005726-29: An open label signal detection study to evaluate the effects of cariprazine on cognitive functioning in patients with schizophrenia in need of adjustment of oral antipsychotic treatment |
|
|
| Not yet recruiting | 4 | 20 | Europe | Capsule, hard, Reagila | Medical University Innsbruck, Gedeon Richter Plc. | Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-001268-58: Investigation of effects of cariprazine in patients with mitochondrial schizophrenia A cariprazine hatásának vizsgálata mitochondriális dysfunkcióval asszociált schizophreniában |
|
|
| Not yet recruiting | 4 | 10 | Europe | Reagila, Capsule, Reagila | Semmelweis University, STIA-POC-2020, Semmelweis University, STIA-POC-2020, Gedeon Richter | Mitochondrial disease associated schizophrenia Mitochondrialis betegséghez társuló schizophrenia, schizophrenia associating with mitochondrial disease schizophrenia, amely mitochondrialis betegséghez társul, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
NCT04843423: Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder |
|
|
| Recruiting | 4 | 15 | Canada | Cariprazine | Dr. Martin A. Katzman | Attention Deficit Hyperactivity Disorder | 12/22 | 04/23 | | |
NCT05384483: Cariprazine Versus Placebo for Social Anxiety Disorder |
|
|
| Not yet recruiting | 4 | 40 | US | Cariprazine, Vraylar®, Placebo | The Medical Research Network, AbbVie | Social Anxiety Disorder | 10/23 | 11/23 | | |
DUAG9, NCT05913947: Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression |
|
|
| Recruiting | 4 | 122 | Europe | Lithium, Litarex, ATC; N05AN01, Cariprazine, Reagila, ATC: N05AX15 | Aalborg University Hospital, Mental Health Center, Glostrup, Mental Health Center North Zealand, Mental Health Department Odense, University Clinic, Psychiatric Center Copenhagen, Rigshospitalet | Depression, Bipolar | 09/24 | 09/24 | | |
| Not yet recruiting | 4 | 2726 | Canada, US | Cariprazine, Vraylar, Aripiprazole/Escitalopram combination, Abilify/ Lexapro, Quetiapine, Seroquel, Lurasidone, Latuda | Massachusetts General Hospital, Patient-Centered Outcomes Research Institute | Bipolar I Disorder, Depression | 02/30 | 02/30 | | |
NCT05060549: Dopamine D3 Receptor Occupancy in Bipolar Depression |
|
|
| Not yet recruiting | 4 | 8 | US | Cariprazine, Vraylar | New York State Psychiatric Institute | Bipolar Depression | 03/25 | 03/25 | | |
NCT05741502: An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine |
|
|
| Recruiting | 4 | 60 | US | Clozapine, Antipsychotics,Other (non-Clozapine), Including Olanzapine, Risperidone, Paliperidone, Quetiapine, Aripiprazole, Ziprasidone, Lurasidone, Cariprazine, and all Typical antipsychotics | Ohio State University | Treatment-resistant Schizophrenia | 03/26 | 06/26 | | |
NCT05933538: Effectiveness of Cariprazine Monotherapy for Treatment of Major Depressive Disorder |
|
|
| Not yet recruiting | 4 | 110 | NA | Cariprazine, Treatment as usual | Sultan Qaboos University | Depressive Disorder, Major | 08/30 | 12/30 | | |
2018-004590-27: Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia |
|
|
| Ongoing | 3 | 300 | Europe | cariprazine, RGH-188, Capsule, hard, Reagila | Gedeon Richter Plc, Gedeon Richter Plc | Adolescent patient (13-<18 years of age) with Schizophrenia, Adolescent patient (13-<18 years of age) with Schizophrenia, Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-004006-26: Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia |
|
|
| Ongoing | 3 | 330 | Europe | cariprazine, RGH-188, Capsule, hard | Allergan Ltd, Allergan Ltd. | Adolescent Patients (13 to 17 years of age) with Schizophrenia, Adolescent Patients (13 to 17 years of age) with Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2018-003164-31: The purpose of this study is to look into the safety and efficacy ofcariprazine as an add-on medication in the treatment of major depressivedisorder. |
|
|
| Not yet recruiting | 3 | 750 | RoW, Europe | Cariprazine, Capsule | Allergan Ltd., Allergan Sales LLC | Major Depressive Disorder, Clinical Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT04519099 / 2017-000818-34: Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia |
|
|
| Recruiting | 3 | 345 | Europe, US, RoW | Cariprazine, Placebo | Allergan, Allergan Ltd | Schizophrenia | 04/22 | 04/22 | | |
NCT05168007: Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia |
|
|
| Enrolling by invitation | 3 | 342 | RoW | WID-RGC20(Cariprazine) 3mg/day, WID-RGC20(Cariprazine) 6mg/day, Placebo for WID-RGC20(Cariprazine) 3mg/day or 6mg/day | Whanin Pharmaceutical Company | Schizophrenia | 07/23 | 07/23 | | |
NCT04777357: A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. |
|
|
| Recruiting | 3 | 380 | US, RoW | Cariprazine, Vraylar, Placebo | AbbVie | Depression, Bipolar I Disorder | 03/27 | 03/27 | | |
NCT03817502 / 2018-004006-26: Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia |
|
|
| Recruiting | 3 | 330 | Europe, US, RoW | Cariprazine, Placebo | Gedeon Richter Plc., Allergan Ltd. | Schizophrenia | 04/25 | 04/25 | | |
NCT05368558: Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia |
|
|
| Active, not recruiting | 3 | 34 | Japan, RoW | Cariprazine, VRAYLAR, Placebo | AbbVie | Schizophrenia | 10/24 | 10/24 | | |
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder |
|
|
| Recruiting | 3 | 280 | US | Cariprazine Flexible Dose | AbbVie | Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD) | 09/25 | 09/25 | | |
| Recruiting | 3 | 30 | Canada | Cariprazine, VRAYLAR®, Placebo | Jayasree Basivireddy | Bipolar I Disorder, Cognitive Impairment | 09/25 | 09/26 | | |
CReW BP-I, NCT06256367: Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder |
|
|
| Recruiting | N/A | 170 | Canada | | AbbVie | Bipolar I Disorder | 07/25 | 07/25 | | |
